DE60032029T2 - Antithrombose agenzien - Google Patents

Antithrombose agenzien Download PDF

Info

Publication number
DE60032029T2
DE60032029T2 DE60032029T DE60032029T DE60032029T2 DE 60032029 T2 DE60032029 T2 DE 60032029T2 DE 60032029 T DE60032029 T DE 60032029T DE 60032029 T DE60032029 T DE 60032029T DE 60032029 T2 DE60032029 T2 DE 60032029T2
Authority
DE
Germany
Prior art keywords
antibody
factor
seq
antibodies
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032029T
Other languages
German (de)
English (en)
Other versions
DE60032029D1 (de
Inventor
C. Frank Audubon BARONE
N. Michael Phoenixville BLACKBURN
Z. Giora Wynnewood FEUERSTEIN
R. John Collegeville TOOMEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE60032029D1 publication Critical patent/DE60032029D1/de
Publication of DE60032029T2 publication Critical patent/DE60032029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
DE60032029T 2000-05-15 2000-10-05 Antithrombose agenzien Expired - Fee Related DE60032029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
US571434 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (2)

Publication Number Publication Date
DE60032029D1 DE60032029D1 (de) 2007-01-04
DE60032029T2 true DE60032029T2 (de) 2007-05-31

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032029T Expired - Fee Related DE60032029T2 (de) 2000-05-15 2000-10-05 Antithrombose agenzien

Country Status (20)

Country Link
US (1) US20050037006A1 (https=)
EP (2) EP1282444B1 (https=)
JP (1) JP2004516236A (https=)
KR (2) KR20070116192A (https=)
CN (2) CN100339132C (https=)
AT (1) ATE345816T1 (https=)
AU (2) AU2000278584B2 (https=)
BR (1) BR0015872A (https=)
CA (1) CA2411369A1 (https=)
CZ (1) CZ20023778A3 (https=)
DE (1) DE60032029T2 (https=)
ES (1) ES2277597T3 (https=)
HU (1) HU225874B1 (https=)
IL (1) IL152831A0 (https=)
MX (1) MXPA02011385A (https=)
NO (1) NO20025463L (https=)
NZ (1) NZ522632A (https=)
PL (1) PL360060A1 (https=)
WO (1) WO2001087339A1 (https=)
ZA (1) ZA200209265B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
JP5307397B2 (ja) 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
BR9913435A (pt) * 1998-08-28 2001-09-25 Genentech Inc Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica

Also Published As

Publication number Publication date
IL152831A0 (en) 2003-06-24
EP1282444A1 (en) 2003-02-12
BR0015872A (pt) 2004-08-03
CN101134107A (zh) 2008-03-05
WO2001087339A1 (en) 2001-11-22
ZA200209265B (en) 2003-10-22
CA2411369A1 (en) 2001-11-22
NO20025463L (no) 2003-01-09
CN100339132C (zh) 2007-09-26
KR20030034071A (ko) 2003-05-01
EP1282444A4 (en) 2004-06-30
HUP0301804A3 (en) 2005-12-28
EP1825864A2 (en) 2007-08-29
JP2004516236A (ja) 2004-06-03
CN1501812A (zh) 2004-06-02
HUP0301804A2 (hu) 2003-08-28
ATE345816T1 (de) 2006-12-15
NO20025463D0 (no) 2002-11-14
US20050037006A1 (en) 2005-02-17
NZ522632A (en) 2005-05-27
MXPA02011385A (es) 2004-01-26
AU7858400A (en) 2001-11-26
DE60032029D1 (de) 2007-01-04
EP1825864A3 (en) 2007-09-12
PL360060A1 (en) 2004-09-06
CZ20023778A3 (cs) 2003-08-13
EP1282444B1 (en) 2006-11-22
HU225874B1 (en) 2007-11-28
ES2277597T3 (es) 2007-07-16
AU2000278584B2 (en) 2006-11-16
KR20070116192A (ko) 2007-12-06

Similar Documents

Publication Publication Date Title
DE69736197T2 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DE60032029T2 (de) Antithrombose agenzien
DE60033814T2 (de) Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers
DE69828154T2 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
AU2000278584A1 (en) Antithrombotic agents
US20020136725A1 (en) Antithrombotic agents
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
CA2243236A1 (en) Anticoagulant agents useful in treatment of thrombosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee